Brainstorm cell therapeutics, inc. announces the phase 3 clinical trial independent data safety monitoring board

Brainstorm cell therapeutics inc. announced that the phase 3 clinical trial independent data safety monitoring board (dsmb) has completed the second, pre-specified interim analysis, of safety outcomes for the first 106 patients who received repeat dosing of nurown® in the phase 3 trial for als patients (nct03280056). the dsmb indicated that the phase 3 clinical trial should continue as planned. brainstorm is conducting a repeat dose, randomized, placebo-controlled phase 3 trial of nurown (200 als participants randomized 1:1 to nurown or placebo) at 6 major us clinical sites, supported by a grant from the california institute for regenerative medicine (cirm clin2-0989). the study is now fully enrolled and will generate top line data in fourth quarter of 2020.
BCLI Ratings Summary
BCLI Quant Ranking